hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes
Source: Therapeutic Advances in Drug Safety - Category: Drugs & Pharmacology Authors: Hancox, J. C., Melgari, D., Dempsey, C. E., Brack, K. E., Mitcheson, J., Ng, G. A. Tags: Letter to the editor Source Type: research
More News: Drugs & Pharmacology